The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
Quick Searches
Selecting one or more of the options below will update the content below.
- Clinical TrialIn-Person
What is this Study about?
We are conducting three separate studies to explore the effects of transcranial Direct Current Stimulation (tDCS) in individuals with Alzheimer’s Disease or Primary Progressive Aphasia. tDCS is a non-invasive therapy that uses low electrical currents to stimulate specific areas of the brain. Previous research has suggested that tDCS can improve symptoms such as language difficulties and may help slow the progression of Alzheimer’s.
Our studies aim to investigate these effects in different contexts, including language therapy and overall mental abilities. Upon completion, participants will receive their study results to help guide their decisions about whether tDCS could be part of a long-term therapy plan.
Eligibility Criteria
Person living with Alzheimer's disease
Recruitment End Date
- Clinical TrialOnline
What is this Study about?
Scientific evidence indicates that healthy lifestyle habits promote brain health and help prevent Alzheimer’s disease.
Our study consists of evaluating a personalized program designed to promote healthy lifestyle habits with the goal of supporting brain health.
This program, called Luci, is available as an online platform with virtual guidance from an advisor. Its purpose is to help participants change their lifestyle habits. It focuses on three areas: physical activity, healthy eating, and intellectual stimulation.
The aim of this study is to determine whether our program helps improve lifestyle habits in these three areas, along with other indicators linked to brain health.
Eligibility Criteria
You are eligible to participate if you:
• Are aged between 50 and 75 years of age
• Have not been diagnosed with a cognitive disorder, such as Alzheimer’s disease
• Wish to adopt healthy lifestyle habits in at least one of the following domains: physical activity, healthy eating, and intellectual stimulation
• Have access to a tablet or computer with an internet connection
• Are able to speak English or French
Recruitment End Date
- Clinical TrialOnline
What is this Study about?
The Communication Bridge 3 Study is focused on helping adults with mild to moderate Primary Progressive Aphasia (PPA), a condition that affects language abilities due to neurodegenerative diseases. The study aims to improve functional communication and life participation by providing structured language and communication support remotely through video conferencing.
Participants work with speech-language pathologists to practice communication techniques and learn strategies to address daily communication challenges. The study involves a series of therapy sessions, assessments, and follow-up evaluations to measure changes in communication and participation over time. By tracking participants' progress, the study hopes to identify effective approaches for enhancing quality of life for those living with PPA and their care partners.Eligibility Criteria
You are eligible to participate if you speak English as a primary language, a confirmed diagnosis of PPA in mild to moderate impairment stage, a communication partner that is willing to participate, and sufficient internet connection.
Recruitment End Date
- Clinical TrialOntario
What is this Study about?
McMaster University, in partnership with Ressam Gardens Memory Care Community, is conducting a study on the effects of brain stimulation in individuals aged 50 and older with dementia or memory loss. The research focuses on using repetitive transcranial magnetic stimulation (rTMS), a non-invasive technique that delivers magnetic pulses to the brain, to enhance cognitive function and balance. The goal is to extend the positive effects of brain stimulation in improving cognition and balance in individuals with dementia.
Eligibility Criteria
You are eligible to participate if you…
1.) Diagnosed with Dementia and/or memory loss by a clinician
2.) Exhibit adequate oral communication skills and cognitive function sufficient to obtain a score ranging between 10-27 on the Mini-Mental State Exam
3.) Walk or stand with or without personnel or assistive devices
4.) Individuals must be greater than or equal to 50 years of age
Recruitment End Date
- Clinical TrialIn-Person
What is this Study about?
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
Eligibility Criteria
60+
Diagnosis of Alzheimer's disease
Must have a study partnerRecruitment End Date
- Clinical TrialIn-Person
What is this Study about?
It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.
Eligibility Criteria
You are eligible to participate if you meet the following criteria:
• Age ≥ 55; females must be post-menopausal
• DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)
• sMMSE ≤ 24
• Clinically significant agitation based on IPA definition
• Stable cognition-enhancing medication for at least 3 months prior to study enrolment
• Availability of a caregiver to accompany participant to study visits and to participate in the study
• Ability to speak English
Recruitment End Date
- Clinical TrialOnline & In-Person
What is this Study about?
To examine the effects of a stress management program on well-being, stress, and cognition in family caregivers of someone with dementia or a related neurodegenerative disorder. We will be recruiting participants from 2023 - 2027.
Eligibility Criteria
- are a primary family caregiver of a person with dementia or a related neurodegenerative disorder.
- have access to a computer with high-speed internet; and feel comfortable using email and Zoom (a secure online meeting platform).
- have a video camera on your device. To ensure safety of participants during the program sessions, it is important that participants turn on their video camera. Keeping the video camera on is also important to build trust within the group sessions and when interacting with the researchers.
- are willing to be randomised to one of 3 groups, even if it is not your preferred group.
- are able to commit to a synchronous 8-week online group-based program (described below) and complete daily prescribed daily home practices.
- are able to commit to three assessment sessions: one baseline assessment, one post-program assessment, one 12-month follow-up assessment.
- agree to audio recording of interview sessions and portions of the assessment that require accurate verbal data collection.
- are able to provide blood samples, potentially after a 12-hour fast.
- are able to travel to a LifeLabs clinic for biomarker collection.
- agree to refrain from participating in new studies or programs during the 8-week study session.
- meet the screening criteria during the pre-screening interview.
- ability to speak English.
Recruitment End Date
Alzheimer Society of Canada
20 Eglinton Avenue West, 16th Floor
Toronto, Ontario M4R 1K8
Information and Referral Line: 1-855-705-4636
Email: [email protected]
Charity registration number: 11878 4925 RR0001
Follow us: